Sandoz Group AG Sponsored ADR (OTCMKTS:SDZNY – Free Report) – Investment analysts at Erste Group Bank lowered their FY2027 earnings estimates for Sandoz Group in a research note issued on Wednesday, October 21st. Erste Group Bank analyst H. Engel now forecasts that the company will post earnings per share of $4.55 for the year, down from their prior estimate of $4.56. Erste Group Bank has a “Strong-Buy” rating on the stock. The consensus estimate for Sandoz Group’s current full-year earnings is $4.15 per share.
Sandoz Group Trading Up 2.6%
SDZNY stock opened at $99.68 on Tuesday. The firm has a 50 day moving average of $87.13 and a 200-day moving average of $83.64. Sandoz Group has a 12-month low of $62.26 and a 12-month high of $100.34.
Sandoz Group Company Profile
Sandoz Group AG is a Switzerland-based pharmaceutical company focused on generic and biosimilar medicines. Its portfolio includes prescription medicines across therapeutic areas such as anti-infectives, immunology, oncology, ophthalmology, respiratory care and cardiovascular treatments. The company also supplies complex generics, including injectable, inhaled and other specialty formulations.
Sandoz serves patients and healthcare providers through a broad international commercial and manufacturing network, with operations and products spanning Europe, North America, Asia and other global markets.
Read More
- Five stocks we like better than Sandoz Group
- Verizon’s Q3 Results Show Why SpaceX’s Spectrum Grab Isn’t a Major Threat
- Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
- Bristol Myers Squibb’s Cancer Breakthrough Could Have Implications Beyond Its Own Stock
- 5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps
Receive News & Ratings for Sandoz Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sandoz Group and related companies with MarketBeat.com's FREE daily email newsletter.
